| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$753 ) |
| | 2025 | 2022 | ALTAY THERAPEUTICS, INC | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43AR081195 | Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD) | 000 | 1 | NIH | 1/6/2025 | -$753 |
| | 2025 | 2022 | ALTAY THERAPEUTICS, INC | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43HL162149 | The development of a transcriptional inhibitor for lung fibrosis. | 000 | 1 | NIH | 10/30/2024 | $0 |
| | 2025 | 2022 | ALTAY THERAPEUTICS, INC | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43CA272146 | Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . | 000 | 1 | NIH | 1/8/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $299,999 ) |
| | 2024 | 2024 | ALTAY THERAPEUTICS, INC | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43HL172594 | The development of a STAT3 inhibitor for lung scleroderma | 000 | 1 | NIH | 5/10/2024 | $299,999 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | ALTAY THERAPEUTICS, INC. | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43CA272146 | Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . | 000 | 1 | NIH | 10/31/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $998,528 ) |
| | 2022 | 2022 | ALTAY THERAPEUTICS, INC. | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43HL162149 | The development of a transcriptional inhibitor for lung fibrosis. | 000 | 1 | NIH | 5/19/2022 | $299,068 |
| | 2022 | 2022 | ALTAY THERAPEUTICS, INC. | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43AR081195 | Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD) | 000 | 1 | NIH | 8/29/2022 | $299,591 |
| | 2022 | 2022 | ALTAY THERAPEUTICS, INC. | 733 INDUSTRIAL RD | SAN CARLOS | CA | 94070-3310 | SAN MATEO | USA | R43CA272146 | Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . | 000 | 1 | NIH | 9/19/2022 | $399,869 |
|
|
